Photo taken from Amol Akhade/Twitter
Oct 21, 2023, 19:37
Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.
Amol Akhade, Senior Consultant in Medical and Hematooncology at the Dr Hitendra Patil’s Suyog Cancer Clinics, Thane, shared on X/Twitter an insight from ESMO23:
“Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO. We have better questions to answer. Like IO resistance. Let’s use our resources better.”
Source: Amol Akhade/Twitter.